Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 124

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 124
---
 to expire in the next
few years, we believe that the newest patent applications will provide protection to the updated products and processes for their manufacture.
The latest patent applications, some of which have matured to patents, are designed to protect various improvements to the earliest filed
patents, including improvements to the process of production, and ready to use formulations that may be administered from pre-filled syringes
and do not require addition of activators prior to use.

The latest family of patent
applications is derived from WO 2017/103924 (filed in China and in other territories), and the objectives the Company aims to achieve
with these applications are to seek to obtain patent protection to cover improved compositions which are being used or which may be used
by the Company in the future. The improved compositions that the Company aims to protect with these applications relate to other hydrogels
that are formed using GelrinC’s conjugates of polyethylene glycol and denatured fibrinogen. In particular, the conjugates are generated
using an improved process that avoids the use of potentially harmful polar organic solvents. The family of patent applications derived
from WO 2017/103924 includes patent application Nos. US 17/554720, EP 3389736, CA 3006695, HK 1260187, IN 201827024148, JP 2021-181190
and IL 259891, which are detailed in the table below. A patent in China, CN 108472413, was recently granted, whereas the other patents
in this family are still in different stages of examination. These other patent applications may not mature into actual granted patents.
Thus, there is a risk that if any one or more family members are not granted, the improved compositions will not be patent protected in
their respective territory.

GelrinP

A second “pipeline product”
of the Company is designated as GelrinP and it is a product using a conjugate of fibrinogen with a polaxamer (Pluronic) for the treatment
of osteoarthritis. The product exhibits thermo-reversible gelation, is water-immiscible and can be delivered using a minimally invasive
application. It is designed to a form of a paste in the cavity upon UVA irradiation.

This product is more viscous
and better suited for the intended purpose of providing relief from chronic conditions including osteoarthritis. This second potential
product is described by the third family